Vergent Bioscience is a biotech company focusing on the development of tumor-targeted molecular imaging molecules for cancer surgery.
Vergent Bioscience has raised $21.5M in total funding. The most recent round was Series B. The last funding was announced in October 2022.
Vergent Bioscience's investors include Colle Capital Partners, Spring Mountain Capital, Windham Venture Partners, Intuitive, Orlando Health Ventures.
Vergent Bioscience is headquartered in Minneapolis, United States.
Vergent Bioscience is a biotech company focusing on the development of tumor-targeted molecular imaging molecules for cancer surgery.
Vergent Bioscience is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vergent Bioscience — Funding & Investors." VCBacked, October 4, 2022, https://www.vcbacked.co/company/vergent-bioscience. Accessed October 29, 2026.
VCBacked. (2022). Vergent Bioscience — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/vergent-bioscience
{{cite web |title=Vergent Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/vergent-bioscience |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated